CCCC
NASD C4 Therapeutics, Inc.$3.03 ↓ -0.03 (-0.98%) Trading Down from the previous close of $3.06, $0.27 below the day’s high of $3.30
- YTD change
- +58.64%
- vs 20-day SMA
- -4.08%
- vs 200-day SMA
- -3.38%
Price ranges
Price & Performance
+0.40 (+14.49%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.1% away from all-time highs of $51.21
- CCCC is up 59% since the beginning of the year
- CCCC is up 35% over the past 12 months
- CCCC is down 14% over the past 1 month
- 32% of all CCCC investors are betting against CCCC
CCCC reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +49.8%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- +2.71%
- vs 8-day SMA
- +0.50%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
